Due to the multiple beneficial effects of GLP-1R agonists in the treatment of diabetes mellitus including weight loss, pharmaceutical companies have developed and introduced GLP-1R agonists as a treatment option for patients with type 2 diabetes mellitus (e.g. ByettaTM (exenatide) and VictozaTM (liraglutide)). Here, GLP1R is linked to type 2 diabetes mellitus.